Teva Pharmaceutical to Cease Production at Plant in Cidra, Puerto Rico
Teva Pharmaceutical Industries Ltd. announced that the company will cease production at its manufacturing facility in Cidra, Puerto Rico during the fourth quarter of 2006.
Petak Tikva, Israel (Aug. 23)-Teva Pharmaceutical Industries Ltd. (www.tevapharm.com) announced that the company will cease production at its manufacturing facility in Cidra, Puerto Rico during the fourth quarter of 2006. Teva says the move is designed to further improve efficiencies, supply chain management, and competitive positioning following its acquisition of Ivax earlier this year.
The former Ivax facility at Cidra has roughly 550 employees and originally manufactured 50 products. Teva says the majority of these products have already been transferred to other manufacturing facilities. Teva expects that the move will achieve an estimated $45 million in cost savings in 2007.
Teva's manufacturing facility for active pharmaceutical ingredients in Puerto Rico is not affected by the closure.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
